Evidence map›Paper›PMID 42156980›Full record

ArticleBritish journal of cancer2026

Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group.

Isabella C Wiest, Lena Dreikhausen, Ralph Keller, Marcos Marin-Galiano, Laurence Albiges, Johannes Meran, Katharina Leucht, Stefan Rieken, Emilio Esteban, Friedemann Zengerling and 11 more

Abstract read
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Isabella C WiestDepartment of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.ORCID http://orcid.org/0009-0004-4848-614X
Lena DreikhausenDepartment of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Ralph KellerAIO-Studien-gGmbH, Berlin, Germany.
Marcos Marin-GalianoM.A.R.C.O. Institute for Clinical Research and Statistics, Düsseldorf, Germany.
Laurence AlbigesGustave Roussy, INSERM, Biothérapies Innovantes U1363, University of Paris Saclay, Villejuif, 94800, France.
Johannes MeranDepartment of Internal Medicine, Hematology and Internal Oncology, Hospital Barmherzige Brueder, Vienna, Austria.
Katharina LeuchtDepartment of Urology, Jena University Hospital, Friedrich-Schiller University, Jena, Germany.
Stefan RiekenUniversitätsklinik & Poliklinik für Strahlentherapie & Radioonkologie, Universitätsmedizin Göttingen (UMG), Göttingen, Germany.
Emilio EstebanDepartment of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain.
Friedemann ZengerlingDepartment of Urology, Ulm University Hospital, Ulm, Germany.
Joseph TintelnotDepartment of Medicine II, University Medical Center Hamburg-Eppendorf, University Hamburg, Hamburg, Germany.ORCID http://orcid.org/0000-0003-4619-9433
Marc-Oliver GrimmDepartment of Urology, Jena University Hospital, Friedrich-Schiller University, Jena, Germany.ORCID http://orcid.org/0000-0003-3084-8654
Farastuk BozorgmehrDept. of Thoracic Oncology, Thoraxklinik, Heidelberg University Hospital and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-8058-8884
Petros ChristopoulosDept. of Thoracic Oncology, Thoraxklinik, Heidelberg University Hospital and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-7966-8980
Alexander SteinHematology-Oncology Practice Eppendorf (HOPE), Hamburg, Germany.ORCID http://orcid.org/0000-0002-9768-0086
Mascha BinderMedical Oncology, Unispital Basel, Basel, Switzerland.
Nicolai HärtelDepartment of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Konrad KlinghammerCharite Universitätsmedizin Berlin, Hämatologie Onkologie, Berlin, Germany.
Viktor GrünwaldUniversity Hospital Essen, Department of Medical Oncology, West German Cancer Center, Essen, Germany.ORCID http://orcid.org/0000-0003-2083-7687
Michael PogorzelskiUniversity Hospital Essen, Department of Medical Oncology, West German Cancer Center, Essen, Germany.
Matthias P EbertDepartment of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. matthias.ebert@medma.uni-heidelberg.de.ORCID http://orcid.org/0000-0003-3228-5138

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe explored the association of immune-related adverse events (irAE), along with prior and concomitant antibiotic and steroid use, on oncological outcomes following immune checkpoint inhibitor (ICI) treatment in various solid tumours.

methodsPooled data from seven trials on ICI therapy across multiple cancer types (head and neck, non-small cell lung cancer, gastroesophageal junctional adenocarcinoma, oesophageal, renal cell, and urothelial carcinoma) was analysed, focusing on overall survival (OS) and progression-free survival (PFS) and antibiotic or steroid use before and during the study.

resultsOf 693 patients, 80 used steroids and 52 used antibiotics prior to the study, while 360 and 331, respectively, used them concomitantly. Lack of prior antibiotic use was associated with longer OS (No vs. Yes: HR 0.552, 95%-CI 0.370-0.822, p = 0.0035) and PFS (No vs. Yes: HR 0.703, 95%-CI 0.485-1.019, p = 0.0625), whereas concomitant antibiotic use had no such effect. Patients with concomitant steroid use demonstrated longer PFS (No vs. Yes: HR 1.359, 95%-CI 1.091-1.693, p = 0.0061). DISCUSSION: Our study confirmed associations between antibiotic and steroid use and ICI efficacy in cancer. Prior, but not concomitant, antibiotic use was linked to reduced OS, supporting the role of microbiome diversity in tumour response. Concomitant steroid use was associated with improved PFS, potentially reflecting its link to irAE occurrence.

Indexed as

Anti-Bacterial AgentsImmune Checkpoint InhibitorsImmunotherapyNeoplasmsSteroidsAgedFemaleGermanyHumansMaleMiddle AgedProgression-Free SurvivalTreatment OutcomeAnti-Bacterial AgentsImmune Checkpoint InhibitorsSteroids

Identifiers

PMID42156980
PMCPMC13427731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.